3ig7
From Proteopedia
(Difference between revisions)
												
			
			| Line 1: | Line 1: | ||
==Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2==  | ==Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2==  | ||
| - | <StructureSection load='3ig7' size='340' side='right' caption='[[3ig7]], [[Resolution|resolution]] 1.80Å' scene=''>  | + | <StructureSection load='3ig7' size='340' side='right'caption='[[3ig7]], [[Resolution|resolution]] 1.80Å' scene=''>  | 
== Structural highlights ==  | == Structural highlights ==  | ||
| - | <table><tr><td colspan='2'>[[3ig7]] is a 1 chain structure with sequence from [  | + | <table><tr><td colspan='2'>[[3ig7]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3IG7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3IG7 FirstGlance]. <br>  | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EFP:N-{1-[CIS-3-(ACETYLAMINO)CYCLOBUTYL]-1H-IMIDAZOL-4-YL}-2-(4-METHOXYPHENYL)ACETAMIDE'>EFP</scene></td></tr>  | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EFP:N-{1-[CIS-3-(ACETYLAMINO)CYCLOBUTYL]-1H-IMIDAZOL-4-YL}-2-(4-METHOXYPHENYL)ACETAMIDE'>EFP</scene></td></tr>  | 
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr>  | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene></td></tr>  | ||
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3igg|3igg]]</td></tr>  | + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3igg|3igg]]</div></td></tr>  | 
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CDK2 ([  | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CDK2 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>  | 
| - | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[  | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Cyclin-dependent_kinase Cyclin-dependent kinase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.22 2.7.11.22] </span></td></tr>  | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[  | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3ig7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ig7 OCA], [https://pdbe.org/3ig7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3ig7 RCSB], [https://www.ebi.ac.uk/pdbsum/3ig7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3ig7 ProSAT]</span></td></tr>  | 
</table>  | </table>  | ||
== Function ==  | == Function ==  | ||
| - | [[  | + | [[https://www.uniprot.org/uniprot/CDK2_HUMAN CDK2_HUMAN]] Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.<ref>PMID:10499802</ref> <ref>PMID:11051553</ref> <ref>PMID:10995386</ref> <ref>PMID:10995387</ref> <ref>PMID:10884347</ref> <ref>PMID:11113184</ref> <ref>PMID:15800615</ref> <ref>PMID:18372919</ref> <ref>PMID:20147522</ref> <ref>PMID:20079829</ref> <ref>PMID:20935635</ref> <ref>PMID:20195506</ref> <ref>PMID:19966300</ref> <ref>PMID:21262353</ref> <ref>PMID:21596315</ref> <ref>PMID:21319273</ref> <ref>PMID:17495531</ref>    | 
== Evolutionary Conservation ==  | == Evolutionary Conservation ==  | ||
[[Image:Consurf_key_small.gif|200px|right]]  | [[Image:Consurf_key_small.gif|200px|right]]  | ||
| Line 34: | Line 34: | ||
==See Also==  | ==See Also==  | ||
| - | *[[Cyclin-dependent kinase|Cyclin-dependent kinase]]  | + | *[[Cyclin-dependent kinase 3D structures|Cyclin-dependent kinase 3D structures]]  | 
== References ==  | == References ==  | ||
<references/>  | <references/>  | ||
| Line 41: | Line 41: | ||
[[Category: Cyclin-dependent kinase]]  | [[Category: Cyclin-dependent kinase]]  | ||
[[Category: Human]]  | [[Category: Human]]  | ||
| + | [[Category: Large Structures]]  | ||
[[Category: Pandit, J]]  | [[Category: Pandit, J]]  | ||
[[Category: 4-aminoimidazole]]  | [[Category: 4-aminoimidazole]]  | ||
Revision as of 03:31, 21 April 2022
Novel CDK-5 inhibitors - crystal structure of inhibitor EFP with CDK-2
  | |||||||||||
Categories: Cyclin-dependent kinase | Human | Large Structures | Pandit, J | 4-aminoimidazole | Atp-binding | Cell cycle | Cell division | Kinase | Mitosis | Nucleotide-binding | Phosphoprotein | Polymorphism | Protein kinase | Serine/threonine protein kinase | Serine/threonine-protein kinase | Transferase

